drug_type
RELEVANT_DRUG
intervention_type
Cell infusion
drug_description
Autologous, gene-modified CAR T cells engineered to express an anti-CD30 chimeric antigen receptor and CCR4 to enhance trafficking to the Hodgkin lymphoma microenvironment; CAR engagement of CD30 triggers T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express an anti‑CD30 chimeric antigen receptor and the chemokine receptor CCR4. CAR binding to CD30 on malignant cells triggers T‑cell activation, cytokine release, proliferation, and targeted cytotoxicity, while CCR4 enhances trafficking to the Hodgkin lymphoma microenvironment via CCL17/CCL22 gradients.
drug_name
ATLCAR.CD30.CCR4
nct_id_drug_ref
NCT06090864